## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM440511

| SUBMISSION TYPE:      | NEW ASSIGNMENT |
|-----------------------|----------------|
| NATURE OF CONVEYANCE: | MERGER         |
| EFFECTIVE DATE:       | 08/01/2017     |

### **CONVEYING PARTY DATA**

| Name                      | Formerly | Execution Date | Entity Type           |
|---------------------------|----------|----------------|-----------------------|
| Ranbaxy Laboratories Inc. |          | 08/01/2017     | Corporation: DELAWARE |

### **RECEIVING PARTY DATA**

| Name:           | Sun Pharmaceutical Industries, Inc. |  |  |
|-----------------|-------------------------------------|--|--|
| Also Known As:  |                                     |  |  |
| Street Address: | 2 Independence Way                  |  |  |
| City:           | Princeton                           |  |  |
| State/Country:  | NEW JERSEY                          |  |  |
| Postal Code:    | 08540                               |  |  |
| Entity Type:    | Corporation: MICHIGAN               |  |  |

#### **PROPERTY NUMBERS Total: 21**

| Property Type        | Number  | Word Mark       |  |  |
|----------------------|---------|-----------------|--|--|
| Registration Number: | 1206693 | EXELDERM        |  |  |
| Registration Number: | 0710474 | BALNETAR        |  |  |
| Registration Number: | 1461632 | DESQUAM-E       |  |  |
| Registration Number: | 0434497 | EURAX           |  |  |
| Registration Number: | 0975809 | HALOG           |  |  |
| Registration Number: | 1257361 | LAC-HYDRIN      |  |  |
| Registration Number: | 1619401 | LAC-HYDRIN FIVE |  |  |
| Registration Number: | 0385885 | LOWILA          |  |  |
| Registration Number: | 0705165 | LOWILA          |  |  |
| Registration Number: | 2467935 | PERNOX          |  |  |
| Registration Number: | 0676451 | SEBULEX         |  |  |
| Registration Number: | 1647847 | ULTRAVATE       |  |  |
| Registration Number: | 2298022 | WESTCORT        |  |  |
| Registration Number: | 4543786 | ULTRAVATE X     |  |  |
| Registration Number: | 4286530 | ABSORICA        |  |  |
| Registration Number: | 4600194 | PARTNERX SHIP   |  |  |
| Registration Number: | 4869110 | PARTNERX SHIP   |  |  |

TRADEMARK

**REEL: 006137 FRAME: 0216** 900418573

| Property Type        | Number   | Word Mark         |  |
|----------------------|----------|-------------------|--|
| Serial Number:       | 86524284 | DESQUAM-X         |  |
| Serial Number:       | 87347095 | LEAVE ACNE BEHIND |  |
| Registration Number: | 5227868  | EURAX             |  |
| Registration Number: | 1002522  | DESQUAM-X         |  |

#### **CORRESPONDENCE DATA**

**Fax Number:** 6095149779

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 609-720-5394

**Email:** general.ip.mailbox@sunpharma.com

Correspondent Name: Sun Pharma

Address Line 1: 2 Independence Way

Address Line 2: Intellectual Property Dept.

Address Line 4: Princeton, NEW JERSEY 08540

| ATTORNEY DOCKET NUMBER: | RLI merger - SPII  |
|-------------------------|--------------------|
| NAME OF SUBMITTER:      | Christine Kenedy   |
| SIGNATURE:              | /christine kenedy/ |
| DATE SIGNED:            | 08/24/2017         |

#### **Total Attachments: 4**

source=RLI - Sun Merger Merger (MI Certification 8.1.2017)#page1.tif source=RLI - Sun Merger Merger (MI Certification 8.1.2017)#page2.tif source=RLI - Sun Merger Merger (MI Certification 8.1.2017)#page3.tif source=RLI - Sun Merger Merger (MI Certification 8.1.2017)#page4.tif

TRADEMARK REEL: 006137 FRAME: 0217

# MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS FILING ENDORSEMENT

This is to Certify that the MERGER DOCUMENT

for

SUN PHARMACEUTICAL INDUSTRIES, INC.

ID NUMBER: 345364

received by facsimile transmission on August 1, 2017 is hereby endorsed.

Filed on August 1, 2017 by the Administrator.

This document is effective on the date filed, unless a subsequent effective date within 90 days after received date is stated in the document.



Sent by Facsimile Transmission

in testimony whereof, I have hereunto set my hand and affixed the Seal of the Department, in the City of Lansing, this 1st day of August, 2017.

Julia Dale, Director

Corporations, Securities & Commercial Licensing Bureau

TRADEMARK REEL: 006137 FRAME: 0218

| MICHIGAN DEP   | ARTMENT OF   | LICENSING AN   | D REGU                                 | LATORY AFFAI                   | RS  |
|--|--|--|--|--------------------------------|---|
| CORPORATIO   | NS, SECURITIE  | (FOR BURE  |  | ENSING BUREA                   |   |
|  | This document is effe<br>subsequent effective<br>data is stated in the d | ctive on the data filed, u<br>date within 90 days after<br>ocument.                    | nless a<br>received                    | =-1                            |   |
| Nemo<br>Debble Santlago-Leracuente, C                                | CP, Sun Pharmaceut   | cal Industries, Inc.   |  |                                |   |
| Address 3 Skyline Drive  |  |  | ND Oads                                | EFFECTIVE DATE:                |   |
| City<br>Hawthorne  | Ştate<br>NY  | _  | IIP Coda<br>10532                      |                                | saumed nemos: December 31,  |
| (A Document will be return   |  | idress you enter above<br>he registered office.  | ن <u>نا</u> ۱                          | Expiration date for vansf      | errad sesumed names apposits in Item 7.   |
| Pursuant to the provisions of Ac<br>undersigned execute the followin | For use<br>Please read<br>t 284, Public Acts of                          | CERTIFICATE (<br>by Parent and Sul<br>d Information and In<br>1872 (profit corporation | bsidiary Castructions                  | Corporations on the last page) | 82 (nonprofit corporations), the  |
| 1. a. The name of each co  | <del></del>  | n and its identificat  | ion numbe                              | r is:                          |   |
| Sun Pharmaceutical Indu  | stries, Inc.   |  |  |                                | 345364  |
| Ranbaxy Laboratories, Inc.   | ).   |  | ·                                      |                                |   |
| b. The name of the con   | stituent that will be  | the surviving corpo  | oretion and                            | its Identification num         | nber is:  |
| Sun Pharmaceutical Indu  | stries, Inc.   |  |  | ,                              | 345384  |
| c. For each subsidiary   | corporation, state:  |  |  |                                |   |
| Name of corporation  |  | Number of d<br>shares or me<br>of each   | embership                              | s me                           | Number of shares or<br>imberships of each class<br>id by the parent corporation |
| Ranbaxy Laboratories, Inc.   |  | 0 common shares  |  |                                | non shares  |
|  |  |  |  |                                |   |
|  |  |  |  |                                |   |
|  |  |  |  | <del></del>                    |   |
|  |  |  | ······································ |                                | •   |
|  |  | ···  |  | <del></del>                    |   |
|  |  |  |  |                                | ·   |

08/01/2017 10:52AM (GMT-04:00)

TRADEMARK REEL: 006137 FRAME: 0219

| d. The manner and basis of converting the shares or memberships of each constituent corporation is as follows:   |
|--|
|  |
| As of the effective date, by virtue of the merger and without any further action on the part of the surviving corporation or the terminating entity, all issued and outstanding securities of Ranbaxy Laboratories, inc. as the terminating entity shall automatically be canceled an retired and shall cease to exist, and no consideration shall be delivered in exchange therefore. |
|  |
|  |
|  |
|  |
| Complete for each constituent corporation that is a nonprofit corporation organized on directorship basis.   |
| e. For a corporation organized on a directorship basis, state (a) a description of the organization of its board and (b) the number, classification, and voting rights of its directors:   |
| ·  |
| N/A  |
|  |
|  |
|  |
|  |
| Complete for Profit Corporations Only, if applicable.  |
| f. The amendments to the Articles or a Restatement of the Articles of Incorporation of the surviving corporation to be effected by the merger are as follows:  |
| N/A  |
|  |
|  |
|  |
|  |
|  |
|  |
| 2. The merger is permitted by the state or country under whose law it is incorporated and each foreign corporation has   |
| 2. The merger is permitted by the state or country under whose law it is incorporated and each foreign corporation has complied with that law in effecting the merger.   |
| 2. The merger is permitted by the state or country under whose law it is incorporated and each fereign corporation has complied with that law in effecting the merger.   |
| complied with that law in effecting the merger.  |
| 2. The merger is permitted by the state or country under whose law it is incorporated and each foreign corporation has complied with that law in effecting the merger.  3. N/A   |
| complied with that law in effecting the merger.  |

08/01/2017 10:52AM (GMT-04:00)

| Ca | mplets for Nonprofit Corporations Only (delete if not applicable)  |
|----|--|
| 4. |  |
| a. | N/A  |
| b. | N/A  |
| 5. | The consent to the merger by the shareholders or members of the parent corporation was obtained.   |
| 6. | (Complete only if a later effective date is desired other then the date of filing. The date must be no more than 90 days after the receipt of this document in this office.)  The merger shall be effective on the1st day of August,2017 |

| Signed this _ | 30th        | day of               | July                           | ' <b>_</b> | 2017 |
|---------------|-------------|----------------------|--------------------------------|------------|------|
| Sun Pharmace  | utical indu | stries, Inc.         |                                |            |      |
| Ву /          | Ro          | Name of              | pa(ent corporation)            |            |      |
|               |             | (Signature of e      | n puthprized officer or agent) |            |      |
| Abhay Gandhi, | Chief Exe   | cutive Officer & Pre | sident                         |            |      |
|               |             | (Tvoe                | or Print Name)                 |            |      |

08/01/2017 10:52AM (GMT-04:00)